首页> 美国卫生研究院文献>Cancers >A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer
【2h】

A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer

机译:一种数学模型用于预测乳腺癌患者患者次级远端转移诊断时期的数学模型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Previously, a consolidated mathematical model of primary tumor (PT) growth and secondary distant metastasis (sdMTS) growth in breast cancer (BC) (CoMPaS) was presented. The aim was to detect the diagnostic periods for visible sdMTS via CoMPaS in patients with different subtypes ER/PR/HER2/Ki-67 (Estrogen Receptor/Progesterone Receptor/Human Epidermal growth factor Receptor 2/Ki-67 marker) of breast cancer. CoMPaS is based on an exponential growth model and complementing formulas, and the model corresponds to the tumor-node-metastasis (TNM) staging system and BC subtypes (ER/PR/HER2/Ki-67). The CoMPaS model reflects (1) the subtypes of BC, such as ER/PR/HER2/Ki-67, and (2) the growth processes of the PT and sdMTSs in BC patients without or with lymph node metastases (MTSs) in accordance with the eighth edition American Joint Committee on Cancer prognostic staging system for breast cancer. CoMPaS correctly describes the growth of the PT in the ER/PR/HER2/Ki-67 subtypes of BC patients and helps to calculate the different diagnostic periods, depending on the tumor volume doubling time of sdMTS, when sdMTSs might appear. CoMPaS and the corresponding software tool can help (1) to start the early treatment of small sdMTSs in BC patients with different tumor subtypes (ER/PR/HER2/Ki-67), and (2) to consider the patient almost healthy if sdMTSs do not appear during the different diagnostic periods.
机译:此前,介绍了乳腺癌(BC)(COMPAS)的母肿瘤(PT)生长和次级远端转移(SDMTS)生长的综合数学模型。目的是通过乳腺癌的不同亚型ER / PR / HER2 / KI-67(雌激素受体/孕激素受体/人表皮生长因子受体2 / Ki-67标记)患者通过COMPAS通过COMPAS检测可见SDMTS的诊断期。 Compas基于指数增长模型和补充配方,并且该模型对应于肿瘤节点转移(TNM)分期系统和BC亚型(ER / PR / HER2 / KI-67)。 COMPAS模型反映了(1)BC的亚型,例如ER / PR / HER2 / KI-67,以及(2)BC患者的PT和SDMTS的生长过程,没有或根据淋巴结转移(MTSS)与八版美国癌症预后分期系统乳腺癌联合委员会。 Compas正确地描述了BC患者的ER / PR / HER2 / KI-67亚型中PT的生长,并有助于计算不同的诊断时期,这取决于SDMTS可能出现的SDMTS的肿瘤量倍增时间。 COMPAS和相应的软件工具可以帮助(1)开始在BC患者(ER / PR / HER2 / KI-67)中的BC患者中的早期治疗小型SDMTS,以及(2)如果SDMTSS,则认为患者几乎健康在不同的诊断期间不会出现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号